Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device: FDA Warning Letter to Happiest Baby, Inc., 2026-06-15
Letter issued · posted to fda.gov .
Subject as published: Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device
TL;DR
At a glance: FDA's Center for Devices and Radiological Health issued a Warning Letter to Happiest Baby, Inc. on 2026-06-15 regarding Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. The letter references 21 CFR 807.81(a)(3). The verbatim letter is published on fda.gov.
Argus analysis
Happiest Baby, Inc. received a Warning Letter from FDA's Center for Devices and Radiological Health, dated 2026-06-15, regarding Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. The letter follows an FDA inspection and is classified by Argus HQ as high severity, consistent with the matters detailed in the letter body below.
The published letter cites 21 CFR 807.81(a)(3). Warning Letters citing these sections generally concern the matters detailed in the letter body below. The full citation language and supporting observations are in the verbatim letter linked below — Argus HQ does not add citations beyond what FDA published.
FDA Warning Letters carry a 15-business-day response window for the recipient to detail corrective actions. Peer compliance teams in the same product category typically use a letter like this one as an external audit trigger, checking whether their own quality system has documented coverage for the cited sections and whether their CAPA log would withstand the same line of inspection questioning.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Happiest Baby, Inc. MARCS-CMS 718306 — June 15, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Medical Devices Recipient: Recipient Name Dr. Harvey Karp Recipient Title Chief Executive Officer Happiest Baby, Inc. 11390 W. Olympic Blvd. Ste. 450 Los Angeles , CA 90064 United States (b)(4) Issuing Office: Center for Devices and Radiological Health United States WARNING LETTER CMS #718306 June 15, 2026 Dear Dr. Karp: During an inspection of your firm located in Los Angeles, CA from July 21, 2025 through July 25, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the SNOO Smart Sleeper and the SNOO Hospital Bundle. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We received responses from Dr. Harvey Karp, CEO, dated August 15, 2025, and February 26, 2026, concerning the observations and discussion items from the inspection. Unapproved Device Violations Our inspection and review of your website and marketing materials revealed that the SNOO Smart Sleeper and the SNOO Hospital Bundle are adulterated under section 501(f)(1) of the Act, 21 U.S.C. § 351(f)(1), and misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o). The SNOO Smart Sleeper and SNOO Hospital Bundle are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the devices as described and marketed. The SNOO Smart Sleeper and SNOO Hospital Bundle are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices without submitting to FDA a notice or other information respecting the significant changes or modifications that your firm made to the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). The SNOO Smart Sleeper was authorized under DEN210039 with the following indications: “The SNOO Smart Sleeper bassinet plus the SNOO Sleep Sack are jointly intended to facilitate a supine position during sleep. Infants who are placed in a supine sleep position are at lower risk of SIDS/SUID. The device is intended for home use by caregivers of infants from birth to 6 months of age, who are not yet able to roll over consistently.” In addition, the Device Description section of FDA’s Decision …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Happiest Baby, Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Happiest Baby, Inc. as of 2026-06-15. Argus ingests new FDA enforcement records daily.
- What FDA violations was Happiest Baby, Inc. cited for?
- The FDA Warning Letter to Happiest Baby, Inc. (issuing office: Center for Devices and Radiological Health) cites: Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. Classification: Warning Letter.
- When did FDA issue the warning letter to Happiest Baby, Inc.?
- FDA issued the letter (MARCS-CMS 718306) on 2026-06-15.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device: FDA Warning Letter to Happiest Baby, Inc., 2026-06-15. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-happiest-baby-inc-2026-06-15-warning-letter
"Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device: FDA Warning Letter to Happiest Baby, Inc., 2026-06-15." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-happiest-baby-inc-2026-06-15-warning-letter.
Argus HQ Research. "Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device: FDA Warning Letter to Happiest Baby, Inc., 2026-06-15." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-happiest-baby-inc-2026-06-15-warning-letter.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_happiest_baby_inc_2026_06_15_warning_letter_2026,
title = {Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device: FDA Warning Letter to Happiest Baby, Inc., 2026-06-15},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-happiest-baby-inc-2026-06-15-warning-letter},
note = {Accessed: July 13, 2026}
}